Xencor is trading 10.05% higher at $33.72 on November 4, 2026, amid broader-market and biotech strength, with no clear company-specific catalyst.
- Major indexes were higher, and XBI gained 2.13%.
- Xencor’s latest XmAb819 Phase 1 update was released October 25; no company-specific announcement clearly accounts for the move.
- Its earnings report was not confirmed as released during the session. News coverage cited post-election biopharma optimism but did not specifically attribute Xencor’s move to it.